There are several HMAs and JAK inhibitors FDA-approved for other indications (and several additional candidates in clinical testing), while FXR agonist obeticholic acid is FDA-approved for the treatment of primary biliary cholangitis, and several FXR agonists are also undergoing clinical investigation for primary scelerosing cholangitis and nonalcoholic steatohepatitis. The gene discussed is NR1H4; the disease is biliary liver cirrhosis.